Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human HK3 Antibodies:
anti-Mouse (Murine) HK3 Antibodies:
anti-Rat (Rattus) HK3 Antibodies:
Go to our pre-filtered search.
Human Polyclonal HK3 Primary Antibody for IHC (p), WB - ABIN392753
Furuta, Nishi, Le Beau, Fernald, Yano, Bell: Sequence of human hexokinase III cDNA and assignment of the human hexokinase III gene (HK3) to chromosome band 5q35.2 by fluorescence in situ hybridization. in Genomics 1997
Show all 4 Pubmed References
Human Polyclonal HK3 Primary Antibody for WB - ABIN392754
Palmieri, Fitzgerald, Shreeve, Hua, Bronder, Weil, Davis, Stark, Merino, Kurek, Mehdorn, Davis, Steinberg, Meltzer, Aldape, Steeg: Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. in Molecular cancer research : MCR 2009
Based on the target-induced catalytic hairpin assembly and bimetallic catalyst, the enzyme-free recycling amplification strategy for sensitive detection of prostate specific antigen (PSA) has been designed
The prepared biosensor can assay from 0 to 500ng/mL of prostate specific antigen (PSA) level within 2h with the detection limit of 1.18ng/mL by the measurement of resistance change. The resistance change was caused by site selective interaction between PSA and PSA-antigen with an inexpensive bench top digital multimeter (5 1/2 digits)
he superwettable f-PSA microchip can accurately detect human serum samples with excellent correlations with chemiluminescence immunoassay in the clinic, demonstrating its great potential as a sensitive and reliable sensing platform for biological analysis and clinical diagnosis.
The 12-week PSA (show PLAG1 Antibodies) response rate was 88% (22/25) and 22% (4/18), median time to PSA (show PLAG1 Antibodies) progression was 18.2 months [95% confidence interval (CI), 8.3 months-not reached) and 3.7 months (95% CI, 2.8-5.6 months), and median time on treatment 21 months (range, 2.6-37.5) and 4.9 months (range, 1.3-23.2), for the AAP (show APEH Antibodies)-naive and post-AAP (show APEH Antibodies) cohorts, respectively.
The results support that u-PSA provides useful information for predicting predicting biochemical recurrence after radical prostatectomy . This can be beneficial to avoid unnecessary adjuvant treatments or to start them earlier for selected patients
this meta-analysis suggests that PSA (show PLAG1 Antibodies) -158G/A polymorphism may be a protecting factor against BPH (show GLI3 Antibodies) in Caucasian populations, but it may enhance the disease risk in Asians.
Developed risk assessment models for North Chinese patients with 4-50 ng/mL PSA to reduce unnecessary prostate biopsies and increase the detection rate of prostate cancer.
Data show positive associations of relative Gal-3 and relative PSA levels in prostate cancer patients, notably at early clinical time course.
Both the extent of comorbidity and the PSA doubling time should be taken into consideration when deciding on appropriate management and/or clinical trial eligibility at the time of PSA failure.
As restaging in advanced prostate cancer patients is often guided by increases in PSA levels, our results demonstrate that disease progression on enzalutamide can occur without rising PSA levels. Therefore, a disease monitoring strategy that includes imaging not entirely reliant on serial serum PSA measurement may more accurately identify disease progression.
Hexokinase expression is highly enriched in neurons compared to astrocytes.
plastid HXK enzyme activities, location, function in signal transduction, and cross talk to plastid GUN1 protein (a (show GPR153 Antibodies) key signaling factor) were investigated. pHXK may be a node of convergence for sugar-mediated and PGE (show LIPF Antibodies)-derived signals.
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Its protein product is a protease present in seminal plasma. It is thought to function normally in the liquefaction of seminal coagulum, presumably by hydrolysis of the high molecular mass seminal vesicle protein. Serum level of this protein, called PSA in the clinical setting, is useful in the diagnosis and monitoring of prostatic carcinoma. Alternate splicing of this gene generates several transcript variants encoding different isoforms.
, HK III
, hexokinase type III
, P-30 antigen
, prostate specific antigen
, prostate-specific antigen
, hexokinase 3 (white cell)